The Patent Finder

Terms ending in 2034

Bayer Pharma Aktiengesellschaft

Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 9,539,218Prevention and Treatment of Thromboembolic Disorders
In force
 · High confidence
Bayer Pharma AktiengesellschaftIn forceHigh confidence
US 10,087,183Forms of Methyl {4,6-Diamino-2-[1 (2-Fluorobenzyl)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL Carbamate
In force
 · Medium confidence
Adverio Pharma GmbHIn forceMedium confidence
US 10,662,188Forms of Methyl {4,6-Diamino-2-[1 (2-Fluorobenzyl)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL Carbamate
In force
 · Medium confidence
Adverio Pharma GmbHIn forceMedium confidence
US 11,203,593Forms of Methyl {4,6-Diamino-2-[1 (2-Fluorobenzyl)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL Carbamate
In force
 · Medium confidence
Adverio Pharma GmbHIn forceMedium confidence
US 12,503,469Forms of Methyl {4,6-Diamino-2-[1 (2-Fluorobenzyl)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL Carbamate
In force
 · Medium confidence
Adverio Pharma GmbHIn forceMedium confidence
US 9,018,258Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof
In force
 · High confidence
Bayer Intellectual Property GmbHIn forceHigh confidence
US 10,183,932Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders
In force
 · Medium confidence
Bayer Pharma AktiengesellschaftIn forceMedium confidence
US 10,226,469Use of Substituted 2,3-Dihydroimidazo[1,2-c]quinazolines for Treating Lymphomas
In force
 · Medium confidence
Bayer Pharma AktiengesellschaftIn forceMedium confidence
US 9,414,797Combination of Contrast Medium and Mammography CT System with a Prespecified Energy Range and Method for Generating Tomographic Mammography CT Images by This Combination
In force
 · High confidence
Siemens Healthineers AGIn forceHigh confidence
US 11,052,128Formulation for Bispecific T-Cell Engagers (BITES)
In force
 · High confidence
Amgen Inc.In forceHigh confidence
9 more term ends in 2034 · Pro
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19.
Upgrade to Pro
13 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited